TF and cancer: Increasing studies indicated that the TF binding‐enhancer region was dramatically altered in DNA methylation profiles and strongly correlated to cell type‐specific gene expression.[10] In breast cancer, aberrant DNA methylation in enhancer regions has been shown to be associated with different molecular subtypes.[10, 11] Therefore, cancer‐specific TFs can be inferred from DNA methylation profiles of enhancer regions containing putative TF binding sites.